DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Bluebird bio acquires Durham, NC, manufacturing site for lentiviral vector production
bluebird bio said today it has acquired a manufacturing facility in Durham, NC, from an undisclosed seller for $11.5 million, with the goal of producing lentiviral vectors for the company’s cell and gene therapies.
Those therapies, bluebird said, include the cerebral adrenoleukodystrophy treatment Lenti-D, as well as LentiGlobin for transfusion-dependent β-thalassemia and severe sickle cell disease and multiple myeloma treatments bb2121 and bb21217.
bluebird said the acquisition was part of a “significant” investment in manufacturing infrastructure that includes expanding in-house expertise, creating an extensive manufacturing network, and increasing manufacturing capacity.
Related Content
-
Community CenterFamily Celebrates 7-Year-Old’s Sickle Cell Cure Thanks to Sister’s Life-Saving GiftOne 7-year-old who suffered his whole li...
-
education & researchSickle Cell Disease – Hydroxyurea: What You Need to KnowIf you have sickle cell disease, your bo...
-
education & researchEffect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysisThe cell adhesion molecule P-selectin pl...
-
news & eventsStep toward gene therapy for sickle cell diseaseA team of researchers at the Stanford Un...
-
news & eventsGeorgia Universities Join NIH-funded National Study of Bone Marrow Transplant for SCDThe Medical College of Georgia (MCG) and...
-
news & eventsAPS Scientific Meeting 2019The American Pain Society will hold its ...
-
news & eventsCTX001 Earns FDA’s Fast Track Status for Treating Sickle Cell DiseaseThe U.S. Food and Drug Administration (F...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.